MRC1 and neoplasm: Furthermore, in a subcutaneously implanted tumor model, we observed that deficiency of MCT1 methylation inhibited tumor progression (Figure 5i–k) and decreased the number of CD206+TAMs in the primary subcutaneous tumors of MCT1 K467R group compared to MCT1 WT group (Figure 5l,m).